Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Jul 23;528(2):368-375.
doi: 10.1016/j.bbrc.2020.02.094. Epub 2020 Feb 19.

Characterization of heteromeric complexes between chemokine (C-X-C motif) receptor 4 and α1-adrenergic receptors utilizing intermolecular bioluminescence resonance energy transfer assays

Affiliations

Characterization of heteromeric complexes between chemokine (C-X-C motif) receptor 4 and α1-adrenergic receptors utilizing intermolecular bioluminescence resonance energy transfer assays

Xianlong Gao et al. Biochem Biophys Res Commun. .

Abstract

Recently, we reported that chemokine (C-X-C motif) receptor 4 (CXCR4) heteromerizes with α1-adrenergic receptors (AR) on the cell surface of vascular smooth muscle cells, through which the receptors cross-talk. Direct biophysical evidence for CXCR4:α1-AR heteromers, however, is lacking. Here we utilized bimolecular luminescence/fluorescence complementation (BiLC/BiFC) combined with intermolecular bioluminescence resonance energy transfer (BRET) assays in HEK293T cells to evaluate CXCR4:α1a/b/d-AR heteromerization. Atypical chemokine receptor 3 (ACKR3) and metabotropic glutamate receptor 1 (mGlu1R) were utilized as controls. BRET between CXCR4-RLuc (Renilla reniformis) and enhanced yellow fluorescent protein (EYFP)-tagged ACKR3 or α1a/b/d-ARs fulfilled criteria for constitutive heteromerization. BRET between CXCR4-RLuc and EYFP or mGlu1R-EYFP were nonspecific. BRET50 for CXCR4:ACKR3 and CXCR4:α1a/b/d-AR heteromers were comparable. Stimulation of cells with phenylephrine increased BRETmax of CXCR4:α1a/b/d-AR heteromers without affecting BRET50; stimulation with CXCL12 reduced BRETmax of CXCR4:α1a-AR heteromers, but did not affect BRET50 or BRETmax/50 for CXCR4:α1b/d-AR. A peptide analogue of transmembrane domain (TM) 2 of CXCR4 reduced BRETmax of CXCR4:α1a/b/d-AR heteromers and increased BRET50 of CXCR4:α1a/b-AR interactions. A TM4 analogue of CXCR4 did not alter BRET. We observed CXCR4, α1a-AR and mGlu1R homodimerization by BiFC/BiLC, and heteromerization of homodimeric CXCR4 with proto- and homodimeric α1a-AR by BiFC/BiLC BRET. BiFC/BiLC BRET for interactions between homodimeric CXCR4 and homodimeric mGlu1R was nonspecific. Our findings suggest that the heteromerization affinity of CXCR4 for ACKR3 and α1-ARs is comparable, provide evidence for conformational changes of the receptor complexes upon agonist binding and support the concept that proto- and oligomeric CXCR4 and α1-ARs constitutively form higher-order hetero-oligomeric receptor clusters.

Keywords: Bimolecular fluorescence complementation assay; Bimolecular luminescence complementation assay; G protein-coupled receptor heteromers; Hetero-oligomer; Homodimer; Stromal cell-derived factor 1α.

PubMed Disclaimer

Figures

Figure 1:
Figure 1:
BRET assays indicate that CXCR4 interacts with α1a/b/d-ARs. Graphs are representative of at least three independent experiments. A/B. HEK293T cells were transfected with a fixed amount of CXCR4-Rluc and increasing amounts of ACKR3-EYFP, α1a/b/d-AR-EYFP, EYFP (A) or mGlu1R-EYFP (B). 48 h after transfection, EYFP fluorescence and luminescence were read as described in Methods. Net BRET (528nm/460nm) was plotted against EYFP/luminescence (YFP/Lum). C. HEK293T cells were transfected with increasing amounts of both CXCR4-Rluc and ACKR3-EYFP or :α1a/b/d-AR-EYFP at a fixed ratio (1:10) in quadruplicate. Raw BRET (528nm/460nm) was plotted against total DNA amounts transfected.
Figure 2:
Figure 2:
Effects of phenylephrine and CXCL12 on BRET between CXCR4 and α1a/b/d-AR. HEK293T cells were co-transfected with a fixed amount of CXCR4-Rluc and increasing amounts α1a-AR-EYFP (A), α1b-AR-EYFP (B) or α1d-AR-EYFP (C). 48 h after transfection, cells were treated with vehicle (=control), phenylephrine (PE, 200 μM) or CXCL12 (500 nM) for 5 min at 37°C before measuring BRET. Top: Representative measurements from a titration BRET experiment. Center: BRET50 from n=4 independent titration BRET experiments. Bottom: BRETmax from n=4 independent titration BRET experiments. *: p<0.05 vs. control.
Figure 3:
Figure 3:
A peptide analogue derived from TM2 of CXCR4 interferes with BRET between CXCR4 and α1a/b/d-ARs. HEK293T cells were co-transfected with a fixed amount of CXCR4-Rluc and increasing amounts of α1a-AR-EYFP (A), α1b-AR-EYFP (B) or α1d-AR-EYFP (C). 48 h after transfection, cells were treated with vehicle (=control), TM2 or TM4 peptides (20 μM) for 15 min at 37°C before measuring BRET. Top: Representative measurements from a titration BRET experiment. Center: BRET50 from n=4 independent titration BRET experiments. *: p<0.05 vs. control. Bottom: BRETmax from n=4 independent titration BRET experiments. *: p<0.05 vs. control.
Figure 4:
Figure 4:
The CXCR4 homodimer interacts with α1a-AR. A/B. Bimolecular luminescence complementation (BiLC, A) and bimolecular fluorescence complementation (BiFC, B) assays to detect dimeric CXCR4. HEK293T cells were co-transfected with CXCR4-L1/2 or CXCR4-V1/2, as indicated. Luminescence was read after the addition of coelenterazine H. N=3. C/D. BiLC and BiFC BRET indicate that the CXCR4 homodimer interacts with α1a-AR. HEK293T cells were co-transfected with a constant amount of CXCR4-L1/2 and with increasing amounts of α1a-AR -EYFP or EYFP (control, C), or with a constant amount of α1a-AR-RLuc or mGlu1R-RLuc and with increasing amounts of CXCR4-V1/2 (control, D). 48 h after transfection, EYFP fluorescence and luminescence were read as described in the Methods. The net BRET (528/460) is plotted against YFP/Lum. The figure is representative of three independent experiments.
Figure 5:
Figure 5:
Homodimeric CXCR4 interacts with homodimeric α1a-AR. A/B. Bimolecular luminescence complementation (BiLC) assays to detect dimeric mGLu1R (A) and dimeric α1a-AR (B). HEK293T cells were co-transfected with mGLu1R-L1/2 or α1a-AR-L1/2, as indicated. Luminescence was read after the addition of coelenterazine H. N=3. C. Combined BiLC and BiFC BRET indicates that the CXCR4 homodimer interacts with the α1a-AR homodimer, but not with the mGlu1R homodimer. HEK293T cells were co-transfected with constant amounts of α1a-AR-L1/2 or mGlu1R-L1/L2 and with increasing amounts of CXCR4-V1/V2. 48 h after transfection, EYFP fluorescence and luminescence were read as described in the Methods. The net BRET (528/460) is plotted against YFP/Lum. The figure is representative of three independent experiments.

Similar articles

Cited by

References

    1. Alexander SP, Christopoulos A, Davenport AP, Kelly E, Marrion NV, Peters JA, Faccenda E, Harding SD, Pawson AJ, Sharman JL, Southan C, Davies JA, Collaborators C, THE CONCISE GUIDE TO PHARMACOLOGY 2017/18: G protein-coupled receptors, Br J Pharmacol 174 Suppl 1 (2017) S17–S129. 10.1111/bph.13878. - DOI - PMC - PubMed
    1. Sharman JL, Benson HE, Pawson AJ, Lukito V, Mpamhanga CP, Bombail V, Davenport AP, Peters JA, Spedding M, Harmar AJ, Nc I, IUPHAR-DB: updated database content and new features, Nucleic Acids Res 41 (2013) D1083–1088. 10.1093/nar/gks960. - DOI - PMC - PubMed
    1. Quitterer U, AbdAlla S, Discovery of Pathologic GPCR Aggregation, Front Med (Lausanne) 6 (2019) 9. 10.3389/fmed.2019.00009. - DOI - PMC - PubMed
    1. Gaitonde SA, Gonzalez-Maeso J, Contribution of heteromerization to G protein-coupled receptor function, Curr Opin Pharmacol 32 (2017) 23–31. 10.1016/j.coph.2016.10.006. - DOI - PMC - PubMed
    1. Franco R, Martinez-Pinilla E, Lanciego JL, Navarro G, Basic Pharmacological and Structural Evidence for Class A G-Protein-Coupled Receptor Heteromerization, Front Pharmacol 7 (2016) 76. 10.3389/fphar.2016.00076. - DOI - PMC - PubMed

Publication types